The Biden administration says it backs a proposal to waive intellectual property rights (IP) for COVID-19 vaccines. How could that impact future investment in biotech? Portfolio Manager Andy Acker explains.
Why US support for waiving intellectual property protections for COVID-19 vaccines does not spell the end of biotech growth.
How investors can utilise carbon futures, both as an active tool to help mitigate carbon emissions and as a potential additional source of returns.
Are you sitting on the sidelines or invested for the long-term?
Tim Winstone, corporate credit portfolio manager, considers the potential opportunities created by the approach of a key European Union regulatory deadline for legacy debt at banks.
The effects of coronavirus are still being felt globally, yet vaccine rollout programmes are allowing progress to be made in reopening economies. This spring update covers the latest developments within the economy and our broad take on income expectations. Vaccination programmes are allowing economies to reopen, which has fuelled optimism within asset markets that economic
John Bennett and Tom O’Hara, European equities portfolio managers, explain why investing in so-called high ESG risk companies can prove to be beneficial as an active manager.
How investors can utilise carbon futures, both as an active tool to help mitigate carbon emissions and as a potential additional source of returns.
Powerful secular themes are still the main driver to long-term tech earnings growth.